Ildongbioscience
1 known investors
South Korean manufacturer of probiotics and pharmaceutical raw materials and health functional foods, part of the Ildong Group.
Also known as Ildong Bioscience · ILDONG BIOSCIENCE CO., LTD. · 일동바이오사이언스
Investors · 1
Company profile
researched Aug 2026Ildong Bioscience Co., Ltd. (일동바이오사이언스) is a South Korean manufacturer specializing in probiotics and pharmaceutical raw materials and health functional food products. The company describes itself as drawing on 70 years of probiotics expertise and markets patented quadruple-coated probiotics positioned around improved stability. Its product listings fall under health care supplements, and it operates a production facility at 17 Poseunggongdan-ro, Poseung-eup, Pyeongtaek-si, Gyeonggi-do.
The company is an affiliate within the Ildong Group and is characterized as a key affiliate specializing in the manufacture of pharmaceutical and probiotics raw materials. Its listed business type is manufacturer, with GMP and ISO certification marks and a headcount reported in the 51-100 range. Ban O Hyun is listed as president. Internal R&D work covers development and licensing of health functional foods and biomaterials, management of research project plans, new product development and analysis of research data, with clinical research experience cited as a preferred qualification for research staff.
Business model
Ildong Bioscience manufactures probiotics and pharmaceutical raw materials and health functional food products, supplying them as a manufacturer and ingredient producer; following the 2025 share transfer, Ildong Pharmaceutical positioned the company as a strategic asset supporting in-house production of functional food ingredients within an integrated health functional food value chain.
Traction
The company reports a workforce of 51-100 people, GMP and ISO certifications, a Pyeongtaek manufacturing plant, and export activity across Australia, China, Malaysia, the United States and Vietnam. It has been recruiting PhD-level R&D staff in Korea with visa sponsorship and a stated 95% conversion rate from one-year contracts to regular employment.
Latest developments
On 30 July 2025 Ildong Pharmaceutical announced the purchase of Ildong Holdings' 22.5% stake in Ildong Bioscience for KRW 14.16 billion, with closing on 31 July 2025; the transaction also transferred a largest-shareholder call option, investor drag-along rights and shareholder tag-along rights, while Ildong Holdings retained a put option.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
Positioned as a key manufacturing affiliate of the Ildong Group for pharmaceutical and probiotics raw materials, with its role in the group's health functional food value chain reinforced by the 2025 intragroup share transfer.
Technology
The company promotes a patented quadruple-coating technology for probiotics aimed at increasing stability, and holds GMP and ISO certification marks. Its research and development activity covers health functional foods and biomaterials, new product development and analysis of related research data.
Go-to-market
Buyers of health care supplements and functional food ingredients, including group affiliate Ildong Pharmaceutical, which sources functional food ingredients for in-house production.
Geography
Headquartered in South Korea with a manufacturing plant in Pyeongtaek-si, Gyeonggi-do. Main export markets listed are Australia, China, Malaysia, the United States and Vietnam.
History
The company's year of establishment is listed as 2016. In July 2025, as part of an Ildong Group portfolio restructuring intended to improve management efficiency, Ildong Pharmaceutical agreed to buy Ildong Holdings' entire 22.5% stake (1,798,347 shares) in Ildong Bioscience for KRW 14.16 billion in cash, closing 31 July 2025, and also assumed contractual rights tied to a stock purchase and shareholder agreement concluded in June-July 2025 with parties including the IBK-Kium Business Restructuring Private Equity Fund.
Compiled by commissioned research from 4 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 1
launches, deals, and filingsIldong Pharmaceutical announced it would purchase 1,798,347 shares (22.5%) of Ildong Bioscience held by Ildong Holdings for KRW 14.16 billion in cash, with the transaction closing on 31 July. The deal transferred Ildong Holdings' entire stake, along with contractual rights including a largest-shareholder call option exercisable between one and three years after the transaction for up to 20% of shares, investor drag-along rights and shareholder tag-along rights; Ildong Holdings retained the put option. The rights had been established under a stock purchase and shareholder agreement signed in June-July of the same year between Ildong Holdings and parties including the IBK-Kium Business Restructuring Private Equity Fund.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 4
primary sources listed
- [Ildong Bioscience] Research and Developmentkowork.kr · web
4 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Ildongbioscience do?
- South Korean manufacturer of probiotics and pharmaceutical raw materials and health functional foods, part of the Ildong Group.
- Who are Ildongbioscience's investors?
- Ildongbioscience's investors include Kiwoom Investment.